Use of RPL27A gene and / or RPL27A protein in the preparation of a drug for treating meningioma
By overexpressing the RPL27A gene and protein, biomaterials were prepared for the treatment of meningiomas, which solved the problem of poor treatment efficacy in existing technologies for meningiomas, and achieved effective inhibition and prevention of metastasis of meningiomas, providing new therapeutic targets and drugs.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- JINAN UNIVERSITY
- Filing Date
- 2024-12-02
- Publication Date
- 2026-06-02
AI Technical Summary
Current treatments for meningiomas are not very effective, especially for high-grade meningiomas with their aggressive growth and metastasis. Surgery carries high risks, chemotherapy has significant side effects, and targeted therapy lacks effective targets, making it difficult to achieve precision medicine and personalized treatment.
By overexpressing or increasing the expression level of the RPL27A gene and/or RPL27A protein, biological materials such as recombinant expression vectors and lentiviral vectors can be prepared for the preparation of drugs to treat or prevent meningiomas, inhibiting meningioma cell proliferation, promoting cell apoptosis, and reducing tumor volume and metastasis.
It significantly inhibits the occurrence, development and metastasis of meningiomas, provides new diagnostic markers and therapeutic drugs, prolongs patient survival, reduces tumor volume and metastasis risk, and reduces chemotherapy side effects.
Smart Images
Figure CN122124206A_ABST